Polycystic Kidney Diseases: all 158 studies

Page 2 of 2. Open to participants first (21), then studies with results posted, then the rest; newest registration first within each.

• Dynamic Measurement of Renal Functional Reserve as a Predictor of Long-Term Renal FunctionStatus unknownNCT03442647Not applicable
• Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease PatientsCompletedNCT03423810Early Phase 1
• Statin Therapy in Patients With Early Stage ADPKDActive, not recruitingNCT03273413Phase 4
• A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT03102632Not applicable
• A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)CompletedNCT03096080Phase 1
• Using Preimplantation Genetic Diagnosis in Autosomal Dominant Polycystic Kidney Disease Patients: a Multicenter Clinical TrialCompletedNCT02948179Not applicable
• High Water Intake in Polycystic Kidney DiseaseCompletedNCT02933268Not applicable
• Analysis of Clinical and Molecular Genetic Data Influencing the Evolution and Response to Therapy of ADPKD Patients (Autosomal Dominant Polycystic Kidney Disease)Status unknownNCT02887729
• A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in EuropeStatus unknownNCT02848521
• Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02776241Not applicable
• The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating PainWithdrawnNCT02746419Not applicable
• Pioglitazone and Lumbar Bone Marrow Fat in Chronic Kidney DiseaseCompletedNCT02739750
• Efficacy of Tolvaptan on ADPKD PatientsStatus unknownNCT02729662Not applicable
• Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101TerminatedNCT02616055Phase 2
• Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)CompletedNCT02558595Phase 2
• Effect of the Aquaretic Tolvaptan on Nitric Oxide SystemCompletedNCT02527863Phase 2
• Clinical Implications of DNA Analysis on ADPKDCompletedNCT02322385
• New Quantitive MRI Parameters in Assessing Kidneys of Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02250287
• The Eurocyst Initiative: Building a Network of ADPKD Reference Centers Across EuropeStatus unknownNCT02187432
• Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney DiseaseCompletedNCT02166489Phase 1
• Evaluation of Gut Bacteria in Patients With Polycystic Kidney DiseaseCompletedNCT02142101
• Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney DiseaseCompletedNCT02140814Phase 2
• The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted RecipientsCompletedNCT02134899Phase 3
• Effects of Somatostatin on Liver in ADPKDCompletedNCT02119052Phase 2/3
• Effects of Somatostatin on ADPKD HeartCompletedNCT02119013Phase 2/3
• Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)Status unknownNCT02115659Phase 3
• Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKDCompletedNCT02112136Not applicable
• ADPKD Cohort StudyCompletedNCT02084849
• Renal Sympathetic Denervation for Reduction of Pain and Improvement of Insulin Sensitivity in Adult Polycystic Kidney DiseaseStatus unknownNCT02062671Not applicable
• Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney DiseaseStatus unknownNCT02055079Phase 3
• Ursodeoxycholic Acid as Treatment for Polycystic Liver DiseaseCompletedNCT02021110Phase 2
• Repository Study of Autosomal Dominant Polycystic Kidney DiseaseWithdrawnNCT01988038
• Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression ControlStatus unknownNCT01932450Phase 2
• At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic ConditionsCompletedNCT01931644
• A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)CompletedNCT01810614Not applicable
• Sirolimus for Massive Polycystic LiverStatus unknownNCT01680250Phase 2/3
• The Vienna RAP Pilot StudyCompletedNCT01632605Not applicable
• Study of Lanreotide to Treat Polycystic Kidney DiseaseStatus unknownNCT01616927Phase 3
• The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney DiseaseTerminatedNCT01589705
• Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal InsufficiencyCompletedNCT01377246Phase 3
• Efficacy Study of Water Drinking on PKD Progression.CompletedNCT01348035
• Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal InsufficiencyTerminatedNCT01223755Phase 2/3
• Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT01114594
• Consortium for Radiologic Imaging Studies of Polycystic Kidney DiseaseCompletedNCT01039987
• Everolimus on CKD Progression in ADPKD PatientsTerminatedNCT01009957Phase 2/3
• Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)Status unknownNCT00890279Phase 2
• Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney DiseaseTerminatedNCT00801268Not applicable
• Open-Label Extension of LOCKCYST TrialStatus unknownNCT00771888Phase 2/3
• Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00759369Not applicable
• Adrenal Functions in Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT00598377Not applicable
• Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain StudyCompletedNCT00571909Not applicable
• Lanreotide as Treatment of Polycystic LiversCompletedNCT00565097Phase 2/3
• CCB Safety Study in Treatment of Hypertension of ADPKDStatus unknownNCT00541853Phase 4
• Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and SafetyCompletedNCT00491517Phase 2
• The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT00410007Not applicable
• Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00346918Phase 3
• Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic GlomerulonephritisCompletedNCT00345137Phase 1
• Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up StudyCompletedNCT00309283Phase 3

← Polycystic Kidney Diseases overview